1
Country: Germany | Funding: $2B
BioNTech is a global leader in mRNA-based immunotherapy. The company was the first to invent and commercialize a COVID-19 vaccine (in partnership with Pfizer). BioNTech is currently developing several personalized immunotherapeutic agents (vaccines) against cancer and infectious diseases, including melanoma, human papillomavirus, non-small cell lung cancer, tuberculosis and malaria. The company's flagship platform, FixVac, enables the creation of ready-to-use mRNA cancer vaccines that can be used off-shelf to a specific indication (fixed-dose vaccines). These vaccines are a fixed combination of unmutated tumor antigens encoded by mRNA, which are frequently expressed in certain types of cancer. The mRNA is delivered using a proprietary RNA-lipoplex delivery system, which is designed to enhance mRNA stability in the body and target antigen-presenting dendritic cells (DCs), the training grounds of our immune system.
BioNTech is a global leader in mRNA-based immunotherapy. The company was the first to invent and commercialize a COVID-19 vaccine (in partnership with Pfizer). BioNTech is currently developing several personalized immunotherapeutic agents (vaccines) against cancer and infectious diseases, including melanoma, human papillomavirus, non-small cell lung cancer, tuberculosis and malaria. The company's flagship platform, FixVac, enables the creation of ready-to-use mRNA cancer vaccines that can be used off-shelf to a specific indication (fixed-dose vaccines). These vaccines are a fixed combination of unmutated tumor antigens encoded by mRNA, which are frequently expressed in certain types of cancer. The mRNA is delivered using a proprietary RNA-lipoplex delivery system, which is designed to enhance mRNA stability in the body and target antigen-presenting dendritic cells (DCs), the training grounds of our immune system.
2
Country: USA | Funding: $925.9M
NeoGenomics is a cancer reference laboratory that provides cancer testing and partnership programs to pathologists and oncologists.
NeoGenomics is a cancer reference laboratory that provides cancer testing and partnership programs to pathologists and oncologists.
3
Country: USA | Funding: $460.5M
Poseida Therapeutics develops differentiated allogeneic cell therapies and genetic medicines using our proprietary genetic engineering platforms. The company develops the piggyBac non-viral DNA delivery system (which enables introduction of large genetic data into the genome) and the Cas-CLOVER site-specific gene editing system (which can be used for precise site-specific deletions, insertions and knockouts in various cell types). Using this platform, the company creates CAR-T therapies with high levels of desired TSCM (stem cell-derived memory T cells) for the treatment of a range of oncological, autoimmune and rare diseases, including multiple myeloma, acute myeloid leukemia and prostate cancer. Poseida was acquired by Roche in early 2025.
Poseida Therapeutics develops differentiated allogeneic cell therapies and genetic medicines using our proprietary genetic engineering platforms. The company develops the piggyBac non-viral DNA delivery system (which enables introduction of large genetic data into the genome) and the Cas-CLOVER site-specific gene editing system (which can be used for precise site-specific deletions, insertions and knockouts in various cell types). Using this platform, the company creates CAR-T therapies with high levels of desired TSCM (stem cell-derived memory T cells) for the treatment of a range of oncological, autoimmune and rare diseases, including multiple myeloma, acute myeloid leukemia and prostate cancer. Poseida was acquired by Roche in early 2025.
4
Country: Poland | Funding: $377.4M
DEBN is a medical device company developing a novel prostate biopsy needle for urologists which reduces infectious complication rate by delivering the optimal antibiotic combination directly to the prostate, precisely at the place where potential infections start.This augmented prophylaxis could save $2B cost of infections' treatment following 5M biopsies worldwide.
DEBN is a medical device company developing a novel prostate biopsy needle for urologists which reduces infectious complication rate by delivering the optimal antibiotic combination directly to the prostate, precisely at the place where potential infections start.This augmented prophylaxis could save $2B cost of infections' treatment following 5M biopsies worldwide.
5
Country: Canada | Funding: $290.2M
Profound Medical Inc is a medical device company providing Magnetic Resonance guided ablation procedure for prostate care.
Profound Medical Inc is a medical device company providing Magnetic Resonance guided ablation procedure for prostate care.
6
Country: USA | Funding: $220M
Paige.AI, stands for Pathology AI Guidance Engine, is a new startup that uses artificial intelligence to fight cancer. The company focus on breast, prostrate and other major cancers, and expects to partner with other medical centers beyond MSK, as well as commercial labs and pharmaceutical companies as it grows and develops its applications.
Paige.AI, stands for Pathology AI Guidance Engine, is a new startup that uses artificial intelligence to fight cancer. The company focus on breast, prostrate and other major cancers, and expects to partner with other medical centers beyond MSK, as well as commercial labs and pharmaceutical companies as it grows and develops its applications.
7
Country: USA | Funding: $208.3M
Halda is developing RIPTAC therapeutics - a new class of precision medicines to defeat cancer.
Halda is developing RIPTAC therapeutics - a new class of precision medicines to defeat cancer.
8
Country: USA | Funding: $130M
Convergent Therapeutics is a pharmaceutical company focused on developing next generation radiopharmaceutical therapies for prostate cancers
Convergent Therapeutics is a pharmaceutical company focused on developing next generation radiopharmaceutical therapies for prostate cancers
9
Country: USA | Funding: $110M
Artera offers an AI-enabled test aimed at personalizing therapy for prostate cancer patients
Artera offers an AI-enabled test aimed at personalizing therapy for prostate cancer patients
10
Country: USA | Funding: $43M
Ezra develops technology for detecting cancer early using MRI & AI. Starting with prostate cancer.
Ezra develops technology for detecting cancer early using MRI & AI. Starting with prostate cancer.
11
Country: USA | Funding: $34.3M
Anixa is a publicly-traded biotechnology company focused on harnessing the body's immune system in the fight against cancer. Anixa's therapeutic portfolio includes a cancer vaccine technology focused on the immunization against α-Lactalbumin to prevent triple negative breast cancer (TNBC), as well as a cancer immunotherapy program which uses a novel type of CAR-T, known as chimeric endocrine receptor T-cell (CER-T) technology.
Anixa is a publicly-traded biotechnology company focused on harnessing the body's immune system in the fight against cancer. Anixa's therapeutic portfolio includes a cancer vaccine technology focused on the immunization against α-Lactalbumin to prevent triple negative breast cancer (TNBC), as well as a cancer immunotherapy program which uses a novel type of CAR-T, known as chimeric endocrine receptor T-cell (CER-T) technology.
12
Country: USA | Funding: $27.8M
Talus Bio is a drug discovery biotech startup that develops drugs targeting undruggable transcription factors using AI.
Talus Bio is a drug discovery biotech startup that develops drugs targeting undruggable transcription factors using AI.
13
Country: Switzerland | Funding: $21.3M
ProteoMediX is specialized in the identification of novel biomarkers for the early detection of cancer. The first product currently developed is a blood-based test that enables the diagnosis of prostate cancer with significantly higher accuracy than today's clinical standard.
ProteoMediX is specialized in the identification of novel biomarkers for the early detection of cancer. The first product currently developed is a blood-based test that enables the diagnosis of prostate cancer with significantly higher accuracy than today's clinical standard.
14
Country: USA | Funding: $19.3M
Image guided laser therapy for prostate cancer in a doctor’s office.
Image guided laser therapy for prostate cancer in a doctor’s office.
15
Country: South Korea | Funding: $17.9M
Deep Bio combines cutting-edge AI algorithms with digital pathology to revolutionize cancer diagnosis. Deep Bio develops AI prostate cancer diagnosis support software
Deep Bio combines cutting-edge AI algorithms with digital pathology to revolutionize cancer diagnosis. Deep Bio develops AI prostate cancer diagnosis support software
16
Country: Canada | Funding: CA$6.8M
Nanostics is focused on development and commercialization of novel, non-invasive diagnostic tests for cancer.
Nanostics is focused on development and commercialization of novel, non-invasive diagnostic tests for cancer.
17
Country: Finland
Top Data Science is an AI startup that’s developing software that can make sense of millions of data points, alert doctors to unseen medical patterns, help them diagnose disease and track patients during treatment.
Top Data Science is an AI startup that’s developing software that can make sense of millions of data points, alert doctors to unseen medical patterns, help them diagnose disease and track patients during treatment.
18
Country: USA
Dendreon was a biotechnology company produces immunotherapy for prostate cancer. Its cancer vaccine uses a patient’s own immune cells, which are collected, processed and infused back into the individual through an intravenous infusion that is completed in three cycles.
Dendreon was a biotechnology company produces immunotherapy for prostate cancer. Its cancer vaccine uses a patient’s own immune cells, which are collected, processed and infused back into the individual through an intravenous infusion that is completed in three cycles.
19
Country: USA | Funding: $1.5M
Bot Image develops software ProstatID - for post processing MRI using cloud based computing, physician workstation integration, and AI image interpretation to provide highly accurate prostate cancer diagnostics.
Bot Image develops software ProstatID - for post processing MRI using cloud based computing, physician workstation integration, and AI image interpretation to provide highly accurate prostate cancer diagnostics.
